1] Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. [2].
Nat Biotechnol. 2013 Sep;31(9):833-8. doi: 10.1038/nbt.2675. Epub 2013 Aug 1.
Prokaryotic type II CRISPR-Cas systems can be adapted to enable targeted genome modifications across a range of eukaryotes. Here we engineer this system to enable RNA-guided genome regulation in human cells by tethering transcriptional activation domains either directly to a nuclease-null Cas9 protein or to an aptamer-modified single guide RNA (sgRNA). Using this functionality we developed a transcriptional activation-based assay to determine the landscape of off-target binding of sgRNA:Cas9 complexes and compared it with the off-target activity of transcription activator-like (TALs) effectors. Our results reveal that specificity profiles are sgRNA dependent, and that sgRNA:Cas9 complexes and 18-mer TAL effectors can potentially tolerate 1-3 and 1-2 target mismatches, respectively. By engineering a requirement for cooperativity through offset nicking for genome editing or through multiple synergistic sgRNAs for robust transcriptional activation, we suggest methods to mitigate off-target phenomena. Our results expand the versatility of the sgRNA:Cas9 tool and highlight the critical need to engineer improved specificity.
原核 II 型 CRISPR-Cas 系统可经改造用于在多种真核生物中靶向基因组修饰。在此,我们通过将转录激活结构域直接连接到无核酸酶 Cas9 蛋白或连接到适配体修饰的单指导 RNA(sgRNA),来构建可用于人细胞中 RNA 引导的基因组调控的系统。利用此功能,我们开发了一种基于转录激活的测定法来确定 sgRNA:Cas9 复合物的脱靶结合图谱,并将其与转录激活子样(TAL)效应物的脱靶活性进行比较。我们的结果表明,特异性图谱取决于 sgRNA,sgRNA:Cas9 复合物和 18 个碱基 TAL 效应物可分别潜在耐受 1-3 和 1-2 个靶标错配。通过设计通过交错切口进行基因组编辑或通过多个协同 sgRNA 进行稳健转录激活的协同要求,我们提出了减轻脱靶现象的方法。我们的结果扩展了 sgRNA:Cas9 工具的多功能性,并突出表明需要对提高特异性进行工程设计。